Japan Geriatric Medicine Market Size, Share, and COVID-19 Impact Analysis, By Therapeutics (Analgesics, Antihypertensive, Statins, Antidiabetic, Proton Pump Inhibitors, Anticoagulant, Antipsychotic, and Others), By Condition (Cardiovascular Diseases, Arthritis & Bone Health, Neurological Disorders, Cancer, Diabetes and Metabolic Disorders, Respiratory Diseases, and Others), and Japan Geriatric Medicine Market Insights, Industry Trend, Forecasts to 2035

Japan Geriatric Medicine Market Insights Forecasts to 2035

• The Japan Geriatric Medicine Market Size is Expected to Grow at a CAGR of around 8.2% from 2025 to 2035
• The Japan Geriatric Medicine Market Size is Expected to Hold a Significant Share by 2035

According to a research report published by Spherical Insights & Consulting, The Japan Geriatric Medicine Market Size is anticipated to hold a significant share by 2035, growing at a CAGR of 8.2% from 2025 to 2035. The Japanese geriatric medicine market is driven by various factors, rapidly aging population, rising incidence of chronic diseases, advancements in elderly care technology, and demand for home-based and long-term care solutions.

Market Overview

Geriatric medicines are specially designed for the health and well-being of older adults. It covers distinctive medical, social and functional needs associated with aging, including prevention of diseases and conditions, diagnosis and conditions common in aging population. Key therapeutics in geriatrics are analgesics, antihypertensives, statins, and proton pump inhibitors. Japan has the world's largest aging population, and the aging population is more susceptible to various diseases like hypertension, coronary heart diseases, stroke, diabetes, neurological disorders and others, which creates the demand for medicines that focus on diagnosis, treatment and prevention of various diseases in the elderly population. The Japanese pharmaceutical companies are focused on the development of innovative elderly friendly drug formulations. The rising shift towards personalized medicine for elderly patients is the key trend in this market. The rising incidence of chronic diseases like cancer and diabetes presents a significant opportunity for growth.

Report Coverage

This research report categorizes the market for the Japan geriatric medicine market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Japan geriatric medicine market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Japan geriatric medicine market.

Driving Factors

Japan has the highest elderly population, which creates the demand for age-specific medical treatment is one of the primary factors for market growth. The elderly population is frequently suffering from chronic illnesses such as hypertension, diabetes, Alzheimer’s and CVD, which fuels the market growth. The growing aging population creates awareness about healthy aging and preventive which further boost the market growth. The technological advancements, such as digital health monitoring tools, telemedicine, and AI-based diagnostics, improve the quality of healthcare services. Additionally, government support and expansion in medical infrastructure positively contribute to the market growth.

Restraining Factors

There are certain kinds of medicines that have an adverse impact on the health of older individuals. Older individuals are highly sensitive to medicines and require a proper prescription of medicines. Excessive consumption of medicines also causes death in geriatrics. Some geriatric medicines are highly expensive, which limits the market growth.

Market Segmentation

The Japan geriatric medicine market share is classified into therapeutics and condition.     

• The antihypertensive segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.   

The Japan geriatric medicine market is segmented by therapeutics into analgesics, antihypertensive, statins, antidiabetic, proton pump inhibitors, anticoagulant, antipsychotic, and others. Among these, the antihypertensive segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. This is due to the wide range of antihypertensive drugs available in the market. Additionally, they help to relax and widen blood vessels.

• The cardiovascular diseases segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period.    

The Japan geriatric medicine market is segmented by condition into cardiovascular diseases, arthritis & bone health, neurological disorders, cancer, diabetes and metabolic disorders, respiratory diseases, and others. Among these, the cardiovascular diseases segment held the highest share in 2024 and is expected to grow at a substantial CAGR during the forecast period. This is due to the rising prevalence of CVD, such as coronary artery disease, heart failure, valvular heart disease, and arrhythmia.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Japan geriatric medicine market, along with a comparative evaluation primarily based on their Therapeutics offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes Therapeutics development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Otsuka Pharmaceutical Co., Ltd
• Astellas Pharma
• Takeda Pharmaceuticals Company Ltd.
• Chugai Pharmaceutical
• Asahi Kasei Pharma
• Other

Recent Developments

• In September 2024, Asahi Kasei Pharma obtains approval to manufacture and sell Cresemba Capsule 40 mg as an additional formulation in Japan.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Japan, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Japan geriatric medicine market based on the below-mentioned segments:

Japan Geriatric Medicine Market, By Therapeutics

• Analgesics
• Antihypertensive
• Statins
• Antidiabetic
• Proton Pump Inhibitors
• Anticoagulant
• Antipsychotic
• Others

Japan Geriatric Medicine Market, By Condition

• Cardiovascular Diseases
• Arthritis & Bone Health
• Neurological Disorders
• Cancer
• Diabetes and Metabolic Disorders
• Respiratory Diseases
• Others